NCT00006033View on ClinicalTrials.gov

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2000

Study Completion Date

June 30, 2004

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

gene therapy

BIOLOGICAL

interleukin-2 gene

DRUG

methotrexate

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00006033 - Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer | Biotech Hunter | Biotech Hunter